(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 October 2012 (04.10.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/130819 A1

(51) **International Patent Classification**:
A61K 9/00 (2006.01) *A61K 31/4418* (2006.01)
A61K 47/12 (2006.01) *A61P 7/02* (2006.01)

(21) **International Application Number**:
PCT/EP2012/055361

(22) **International Filing Date**:
27 March 2012 (27.03.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
11305347.4 29 March 2011 (29.03.2011) EP
61/499,941 22 June 2011 (22.06.2011) US

(71) **Applicant** *(for all designated States except US)*: **SANOFI** [FR/FR]; 54, rue La Boétie, F-75008 Paris (FR).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **KAMM, Walter** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **BUSSEMER, Till** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **ANDERT, Doris** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **KÜHN, Bernd** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **TODT, Ernst-Josef** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE).

(74) **Agent**: **THEN, Johann**; c/o Sanofi-Aventis Deutschland GmbH, Patents Germany, Industriepark Höchst, Geb. K 801, 65926 Frankfurt am Main (DE).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2012/130819 A1

(54) **Title**: OTAMIXABAN FORMULATIONS WITH IMPROVED STABILITY

(57) **Abstract**: The invention relates to a pharmaceutical composition comprising methyl (2R.3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable acidic reacting compound or to an aqueous solution or dispersion of the composition as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.